GlassScriptPhysician profile
Dagoberto Balderas
NPI 1699835843
$25,335.92
in general payments reported to CMS, 2019-2025
74 companies · $3,405 in 2025
The $3,405 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,353 · 2020: $3,400 · 2021: $3,550 · 2022: $4,238 · 2023: $3,795 · 2024: $3,594 · 2025: $3,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Entertainment: $71.38 · Education: $26.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,696.64 |
| Entertainment | $71.38 |
| Education | $26.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,966.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,901.77 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $2,160.48 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $1,779.88 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,717.52 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,445.08 | 2019-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,418.13 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $1,003.82 | 2019-2025 | |
| Amgen INC. | $992.65 | 2019-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $757.77 | 2019-2020 | |
| Pfizer INC. | $713.22 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $693.94 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $575.76 | 2019-2023 | |
| Antares Pharma, INC. | $456.29 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Takeda Pharmaceuticals U.S.A., INC. | $415.08 | 2019-2021 |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $376.78 | 2021-2025 | Proclaim, Afinion 2 |
| Indivior INC. | $307.34 | 2023-2025 | Sublocade |
| Eisai INC. | $268.77 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $261.36 | 2022-2025 | Livalo, Seglentis, Zoryve |
| Astellas Pharma US INC | $214.79 | 2019-2025 | Veozah |
| Corcept Therapeutics | $210.38 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $203.23 | 2022-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $188.64 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $174.37 | 2021 | |
| Exact Sciences Corporation | $163.01 | 2023-2025 | Cologuard Collection Kit |
| Ironshore Pharmaceuticals INC. | $156.76 | 2024 | |
| Tms Neurohealth Centers INC. | $130.92 | 2025 | Tms Neurohealth Centers INC. |
| Noven Therapeutics, LLC | $128.42 | 2023-2025 | Xelstrym |
| Amarin Pharma, INC. | $127.54 | 2020-2021 | |
| Radius Health, INC. | $123.54 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $119.04 | 2024-2025 | Gemtesa, Myfembree |
| Zoll Respicardia, INC. | $118.19 | 2024 | Remede System |
| Corium, LLC | $111.00 | 2023-2024 | Azstarys |
| Dexcom, INC. | $110.07 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $109.46 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Tris Pharma INC | $106.64 | 2023-2024 | Dyanavel Xr |
| Genentech USA, INC. | $102.11 | 2019-2022 | |
| Ibsa Pharma INC. | $95.42 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $90.85 | 2025 | Spravato |
| Inspire Medical Systems, INC. | $80.29 | 2024 | Inspire |
| Shield Therapeutics INC | $79.13 | 2023-2024 | Accrufer |
| Medtronic, INC. | $76.01 | 2022-2024 | Vanta Adaptivestim, Synchromedii |
| Optos, INC. | $71.38 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Impulse Dynamics (USA) INC. | $70.46 | 2023 | Optimizer |
| Novartis Pharmaceuticals Corporation | $69.12 | 2023 | Leqvio |
| Myovant Sciences INC. | $67.20 | 2021 | |
| Idorsia Pharmaceuticals US INC | $62.74 | 2023 | Quviviq |
| Tolmar, INC. | $53.73 | 2023-2025 | Jatenzo |
| Teva Pharmaceuticals USA, INC. | $49.04 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.40 | 2024-2025 | Caplyta |
| Mylan Specialty L.P. | $45.44 | 2023 | Yupelri |
| Horizon Therapeutics Plc | $40.61 | 2020 | |
| Supernus Pharmaceuticals, INC. | $38.98 | 2022-2023 | Qelbree, Xyosted, Tlando |
| Collegium Pharmaceutical, INC. | $38.45 | 2025 | Jornay Pm |
| Orexo US, INC. | $36.40 | 2019 | |
| Greer Laboratories, INC. | $36.35 | 2024 | Oralair |
| Shire North American Group INC | $34.34 | 2019 | |
| Acerus Pharmaceuticals Corporation | $31.57 | 2022 | |
| Braeburn INC. | $27.26 | 2023 | Brixadi |
| Abiomed | $27.21 | 2024 | Impella |
| Kaleo, INC. | $26.89 | 2019 | |
| Hologic Sales and Service, LLC | $26.85 | 2024 | Aptima |
| Djo, LLC | $26.67 | 2020 | |
| Adlon Therapeutics L.P. | $21.19 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.58 | 2025 | |
| Medicomp INC | $20.10 | 2021 | |
| Jazz Pharmaceuticals INC. | $18.79 | 2021 | |
| Spinal Simplicity, LLC | $16.05 | 2025 | Ha Minuteman G3-R |
| Itamar Medical INC | $15.16 | 2023 | Watchpatone |
| Halozyme INC | $14.89 | 2023 | |
| Lundbeck LLC | $13.66 | 2022 | |
| Redhill Biopharma INC. | $12.47 | 2020 | |
| Vbi Vaccine (Delaware) INC. | $12.42 | 2022 | |
| Circassia INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dagoberto Balderas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.